دیگر

Obinutuzumab, ibrutinib, and venetoclax in untreated CLL with deletion(17p)/TP53 mutation; NOTCH2 mutants promote chemo-resistance in DLBCL; and the role of DBY/HLA class II complexes in chronic GVHD

0

0

0 بازدیدها· 09/14/23

Blood Podcast
0 مشترکین

که در

In this week's episode, we'll discuss the findings from the final analysis of the CLL2-GIVe trial, learn how NOTCH2 mutants promote resistance to chemotherapy in diffuse large B-cell lymphoma, and discuss the role of DBY/HLA class II complexes in chronic graft-versus-host disease.

بیشتر نشان بده، اطلاعات بیشتر

0 نظرات

تا بعدی

پخش خودکار

صفحه اصلی

بیشتر کاوش کنید

کمک